$HLVX
HilleVax, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023042052 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.603M $7.231M
YoY Change 44.26% 81.59%
% of Gross Profit
Research & Development $27.31M $22.95M
YoY Change 105.09% 160.06%
% of Gross Profit
Depreciation & Amortization $400.0K $100.0K
YoY Change
% of Gross Profit
Operating Expenses $33.91M $30.18M
YoY Change 89.53% 135.67%
Operating Profit -$33.91M -$30.18M
YoY Change 89.53% 135.67%
Interest Expense $717.0K $500.0K
YoY Change 249.76% -43.69%
% of Operating Profit
Other Income/Expense, Net $2.096M $2.282M
YoY Change 92.82% -105.55%
Pretax Income -$31.82M -$27.90M
YoY Change 89.32% -48.26%
Income Tax
% Of Pretax Income
Net Earnings -$31.82M -$27.90M
YoY Change 89.32% -48.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.81 -$0.74
Diluted Earnings Per Share -$0.81 -$0.74
COMMON SHARES
Basic Shares Outstanding 39.22M 39.20M
Diluted Shares Outstanding 39.04M 37.95M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $324.4M $244.1M
YoY Change 11.08% -22.43%
Cash & Equivalents $208.5M $158.4M
Short-Term Investments $115.9M $85.68M
Other Short-Term Assets $8.785M $8.989M
YoY Change 8.54% 83.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $333.2M $253.0M
YoY Change 11.01% -20.8%
LONG-TERM ASSETS
Property, Plant & Equipment $13.74M $13.14M
YoY Change 2190.67% -34.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $22.00K $23.00K
YoY Change 4.76% 9.52%
Total Long-Term Assets $33.77M $33.48M
YoY Change 54.06% 54.11%
TOTAL ASSETS
Total Short-Term Assets $333.2M $253.0M
Total Long-Term Assets $33.77M $33.48M
Total Assets $367.0M $286.5M
YoY Change 13.94% -16.03%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.287M $151.0K
YoY Change 275.66% -97.5%
Accrued Expenses $12.89M $17.65M
YoY Change 67.39% 174.93%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $18.96M $18.34M
YoY Change 119.6% 46.59%
LONG-TERM LIABILITIES
Long-Term Debt $25.04M $24.84M
YoY Change 428.56% 428.74%
Other Long-Term Liabilities $1.096M $922.0K
YoY Change 189.18% 1038.27%
Total Long-Term Liabilities $26.13M $25.76M
YoY Change 410.83% 439.07%
TOTAL LIABILITIES
Total Short-Term Liabilities $18.96M $18.34M
Total Long-Term Liabilities $26.13M $25.76M
Total Liabilities $68.34M $67.76M
YoY Change 95.91% 77.95%
SHAREHOLDERS EQUITY
Retained Earnings -$351.6M -$319.8M
YoY Change 44.21% 40.87%
Common Stock $650.6M $538.9M
YoY Change 22.52% 1.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $298.6M $218.8M
YoY Change
Total Liabilities & Shareholders Equity $367.0M $286.5M
YoY Change 13.94% -16.03%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$31.82M -$27.90M
YoY Change 89.32% -48.26%
Depreciation, Depletion And Amortization $400.0K $100.0K
YoY Change
Cash From Operating Activities -$26.81M -$22.42M
YoY Change 37.14% 69.7%
INVESTING ACTIVITIES
Capital Expenditures $2.190M $4.839M
YoY Change -1283.78%
Acquisitions
YoY Change
Other Investing Activities -$28.99M -$85.11M
YoY Change
Cash From Investing Activities -$31.18M -$89.95M
YoY Change 16752.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 108.1M 10.20M
YoY Change -3933.51% -95.33%
NET CHANGE
Cash From Operating Activities -26.81M -22.42M
Cash From Investing Activities -31.18M -89.95M
Cash From Financing Activities 108.1M 10.20M
Net Change In Cash 50.12M -102.2M
YoY Change -322.25% -149.84%
FREE CASH FLOW
Cash From Operating Activities -$26.81M -$22.42M
Capital Expenditures $2.190M $4.839M
Free Cash Flow -$29.00M -$27.26M
YoY Change 49.76% 106.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001888012
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41365
dei Entity Registrant Name
EntityRegistrantName
HILLEVAX, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0545060
dei Entity Address Address Line1
EntityAddressAddressLine1
75 State Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100 - #9995
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02109
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
213-5054
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
HLVX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39216931
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158375000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279401000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
85675000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8989000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11212000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
253039000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
290613000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13143000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5586000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18686000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
19359000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
22000
CY2023Q2 us-gaap Assets
Assets
286522000
CY2022Q4 us-gaap Assets
Assets
317211000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
151000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4744000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17648000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8210000
CY2023Q2 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
102000
CY2022Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
55000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
437000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
37000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
18338000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13046000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23664000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
21569000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24835000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
14792000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
922000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
575000
CY2023Q2 us-gaap Liabilities
Liabilities
67759000
CY2022Q4 us-gaap Liabilities
Liabilities
49982000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39216931
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39240746
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38049186
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37656037
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
538865000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
532499000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-322000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-281000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319784000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-264993000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
218763000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267229000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
286522000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
317211000
CY2023Q2 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
22953000
CY2022Q2 hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
8826000
hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
46117000
hlvx Research And Development Expense Excluding In Progress Research And Development
ResearchAndDevelopmentExpenseExcludingInProgressResearchAndDevelopment
15037000
hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
2500000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7231000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3982000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13026000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6585000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
30184000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
12808000
us-gaap Operating Expenses
OperatingExpenses
59143000
us-gaap Operating Expenses
OperatingExpenses
24122000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30184000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12808000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59143000
us-gaap Operating Income Loss
OperatingIncomeLoss
-24122000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2453000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
334000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5027000
us-gaap Investment Income Interest
InvestmentIncomeInterest
340000
CY2023Q2 us-gaap Interest Expense
InterestExpense
500000
CY2022Q2 us-gaap Interest Expense
InterestExpense
888000
us-gaap Interest Expense
InterestExpense
949000
us-gaap Interest Expense
InterestExpense
2952000
CY2023Q2 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
CY2022Q2 hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
8818000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
13196000
CY2022Q2 hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
34396000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
51469000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
6151000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
43575000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
329000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-20000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
274000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-38000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2282000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41121000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4352000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-97694000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-27902000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-53929000
us-gaap Net Income Loss
NetIncomeLoss
-54791000
us-gaap Net Income Loss
NetIncomeLoss
-121816000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-37000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-37000
CY2023Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Plan Amendments Tax Effect
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansPlanAmendmentsTaxEffect
-3000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Plan Amendments Tax Effect
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansPlanAmendmentsTaxEffect
-4000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27942000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53929000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54832000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-121816000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.03
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.3
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.3
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37951735
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37951735
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26512881
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26512881
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37853176
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37853176
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16685372
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16685372
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
243061000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3246000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
318000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-37000
CY2023Q2 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-3000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-27902000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
218763000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-168372000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
209515000
CY2022Q2 hlvx Stock Issued During Period Value Conversion Of Notes And Accrued Interest Into Common Shares
StockIssuedDuringPeriodValueConversionOfNotesAndAccruedInterestIntoCommonShares
215364000
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
100020000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
556000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-53929000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
303154000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
267229000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5888000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
318000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
160000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-37000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
-4000
us-gaap Net Income Loss
NetIncomeLoss
-54791000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
218763000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-100757000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
209515000
hlvx Stock Issued During Period Value Conversion Of Notes And Accrued Interest Into Common Shares
StockIssuedDuringPeriodValueConversionOfNotesAndAccruedInterestIntoCommonShares
215364000
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
100020000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
828000
us-gaap Net Income Loss
NetIncomeLoss
-121816000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
303154000
us-gaap Profit Loss
ProfitLoss
-54791000
us-gaap Profit Loss
ProfitLoss
-121816000
us-gaap Depreciation
Depreciation
106000
us-gaap Share Based Compensation
ShareBasedCompensation
5888000
us-gaap Share Based Compensation
ShareBasedCompensation
828000
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
0
hlvx Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
13196000
hlvx Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
51469000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
43575000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
673000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
431000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
255000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
81000
us-gaap Paid In Kind Interest
PaidInKindInterest
205000
us-gaap Paid In Kind Interest
PaidInKindInterest
21000
hlvx Research And Development In Process With Related Party
ResearchAndDevelopmentInProcessWithRelatedParty
2500000
hlvx Net Amortization Of Premiums And Discounts On Marketable Securities
NetAmortizationOfPremiumsAndDiscountsOnMarketableSecurities
-603000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-42000
hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
48000
hlvx Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
-692000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2223000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4750000
hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-269000
hlvx Increase Decrease In Accounts Payable Accrued Expenses And Other Long Term Liabilities Related Parties
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLongTermLiabilitiesRelatedParties
-2531000
hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
5131000
hlvx Increase Decrease In Accounts Payable Accrued Liabilities And Other Long Term Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLongTermLiabilities
550000
hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
0
hlvx Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
717000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
47000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
2821000
hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
2495000
hlvx Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
323000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38371000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23925000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7824000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
85109000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92933000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2500000
hlvx Proceeds From Issuances Of Stock Under Employee Stock Purchase Plan
ProceedsFromIssuancesOfStockUnderEmployeeStockPurchasePlan
318000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
230006000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
16569000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
9800000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
4665000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
160000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10278000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
218102000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-121026000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
191677000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
281032000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
124566000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
160006000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
316243000
us-gaap Interest Paid Net
InterestPaidNet
461000
us-gaap Interest Paid Net
InterestPaidNet
30000
hlvx Noncash Or Part Noncash Operating Lease
NoncashOrPartNoncashOperatingLease
20317000
hlvx Unpaid Initial Public Offering Costs
UnpaidInitialPublicOfferingCosts
1724000
hlvx Unpaid Property And Equipment Purchases
UnpaidPropertyAndEquipmentPurchases
1412000
hlvx Conversion Of Convertible Promissory Notes And Interest Into Common Stock
ConversionOfConvertiblePromissoryNotesAndInterestIntoCommonStock
215364000
hlvx Conversion Of Warrant Liability Into Equity
ConversionOfWarrantLiabilityIntoEquity
100020000
hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
217000
hlvx Accreted Final Interest Payment Fees
AccretedFinalInterestPaymentFees
70000
CY2022Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1.681
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
13529750
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
17
CY2022Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
209500000
CY2022Q2 hlvx Underwriting Discounts Commissions And Offering Costs
UnderwritingDiscountsCommissionsAndOfferingCosts
20500000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
85712000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
18000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
55000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
85675000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
hlvx Impairment Of Assets Measured And Carried At Fair Value
ImpairmentOfAssetsMeasuredAndCarriedAtFairValue
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The preparation of the Company’s unaudited condensed consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s condensed consolidated financial statements and accompanying notes. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to accruals for research and development expenses, and prior to the Company's IPO, the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
CY2023Q2 hlvx Impairment Of Assets Measured And Carried At Fair Value
ImpairmentOfAssetsMeasuredAndCarriedAtFairValue
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q2 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
1317580
CY2022Q2 hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2218351
hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
1404701
hlvx Weighted Average Unvested Shares Excluded From Computation Of Earnings Per Share Amount
WeightedAverageUnvestedSharesExcludedFromComputationOfEarningsPerShareAmount
2346789
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5626920
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3636444
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13249000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5587000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
106000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13143000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5586000
CY2023Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
100000
CY2023Q2 hlvx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
12818000
CY2022Q4 hlvx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
3510000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2667000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4018000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1106000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
307000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1057000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
375000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
17648000
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
8210000
us-gaap Operating Lease Payments
OperatingLeasePayments
1742000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
158375000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
279401000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1631000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
160006000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
281032000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
779000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1559000
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y11M15D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2023Q2 hlvx Debt Instrument Carrying Amount Including Paid In Kind Interest
DebtInstrumentCarryingAmountIncludingPaidInKindInterest
25293000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
458000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
24835000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1743000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3584000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3688000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3784000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3860000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
21075000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
37734000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
10647000
CY2023Q2 hlvx Lessee Operating Lease Tenant Improvement Reimbursements
LesseeOperatingLeaseTenantImprovementReimbursements
2986000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
24101000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
437000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23664000
us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
the Company made matching contributions equal to 100% of the employee’s contributions, subject to a maximum of 4% of eligible compensation. The Company made matching contributions of $0.1 million and $0.4 million, respectively, during the three and six months ended June 30, 2023. The Company did not make any matching contributions during the three and six months ended June 30, 2022.
CY2022Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2022Q4 hlvx Defined Contribution Plan Maximum Eligible Compensation
DefinedContributionPlanMaximumEligibleCompensation
0.04
CY2023Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2023Q2 hlvx Accumulated Paid In Kind Interest Amount
AccumulatedPaidInKindInterestAmount
293000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
719000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1599000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
8433000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
13303000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
10645000
CY2023Q2 hlvx Principal Payments Interest Payments And Final Payment Fee
PrincipalPaymentsInterestPaymentsAndFinalPaymentFee
34699000
CY2023Q2 hlvx Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
9406000
CY2023Q2 hlvx Long Term Debt Net Of Interest Pik Interest And Back End Fee
LongTermDebtNetOfInterestPikInterestAndBackEndFee
25293000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.04
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.029
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.041
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.019
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.926
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.959
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.929
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.917
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.959
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.834
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.929
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3246000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
556000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5888000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
828000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
16.77
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.36
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.31
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
31600000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1584709
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
759266
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
77761
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0.001
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
344872
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0.001
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1921342
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
18
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
12200000
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8271157

Files In Submission

Name View Source Status
0000950170-23-042052-index-headers.html Edgar Link pending
0000950170-23-042052-index.html Edgar Link pending
0000950170-23-042052.txt Edgar Link pending
0000950170-23-042052-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hlvx-20230630.htm Edgar Link pending
hlvx-20230630.xsd Edgar Link pending
hlvx-ex10_2.htm Edgar Link pending
hlvx-ex10_3.htm Edgar Link pending
hlvx-ex31_1.htm Edgar Link pending
hlvx-ex31_2.htm Edgar Link pending
hlvx-ex32_1.htm Edgar Link pending
hlvx-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
hlvx-20230630_cal.xml Edgar Link unprocessable
hlvx-20230630_def.xml Edgar Link unprocessable
hlvx-20230630_pre.xml Edgar Link unprocessable
hlvx-20230630_lab.xml Edgar Link unprocessable
hlvx-20230630_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending